Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal
- Sponsor
- Beijing Municipal Administration of Hospitals
- Study ID
- NCT06707129
- Status
- Recruiting
Conditions
- Non-alcoholic Fatty Liver Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- life-style — OTHERThe patients were given health education and lifestyle intervention guidance, followed by lifestyle adjustment for at least 1 year and no more than 3 years, and a second liver biopsy was performed to evaluate liver histological changes.
Study Details
Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.
Key Dates
- First listed
- Nov 27, 2024
- Start date
- Aug 1, 2024
- Status verified
- Nov 2024
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: Case groupAfter successful patient screening and enrollment, visits will be conducted every 6 months to collect the following information: Physical examination, accompanying diseases, hematology: blood routine, coagulation function, serology, imaging, body fat measurement, liver puncture information (if applicable). Lifestyle questionnaire: Dietary characteristics, sleep/wake time, daily sitting time, exercise duration, exercise mode. Health education and lifestyle intervention guidance should be provided to patients based on exercise mode. When adjusting lifestyle for at least 1 year and no more than 3 years, a second liver biopsy should be performed to evaluate liver histological changes.
Primary Outcome Measure
Reversal of NASH liver fibrosis [ Time Frame: 12 months ]
Central Contacts
- Minghui Li+8613693259096
- Weihua Cao+8618811333129
Related Studies
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseasePHASE2 · Not Yet Recruiting · Justin Ryder · Chicago, Illinois
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- The Olmsted NAFLD Epidemiology Study (TONES)Recruiting · Mayo Clinic · Rochester, Minnesota
- AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)Recruiting · AdventHealth Translational Research Institute · Orlando, Florida